326 related articles for article (PubMed ID: 21051988)
1. Serum hCG level and rising world health organization score at second-line chemotherapy (pulse dactinomycin): poor prognostic factors for methotrexate-failed low-risk gestational trophoblastic neoplasia.
Kang WD; Kim CH; Cho MK; Kim JW; Cho HY; Kim YH; Choi HS; Kim SM
Int J Gynecol Cancer; 2010 Nov; 20(8):1424-8. PubMed ID: 21051988
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group study.
Covens A; Filiaci VL; Burger RA; Osborne R; Chen MD;
Cancer; 2006 Sep; 107(6):1280-6. PubMed ID: 16900525
[TBL] [Abstract][Full Text] [Related]
4. Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia.
Winter MC; Tidy JA; Hills A; Ireson J; Gillett S; Singh K; Hancock BW; Coleman RE
Gynecol Oncol; 2016 Dec; 143(3):565-570. PubMed ID: 27756557
[TBL] [Abstract][Full Text] [Related]
5. Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia.
Yarandi F; Eftekhar Z; Shojaei H; Kanani S; Sharifi A; Hanjani P
Int J Gynaecol Obstet; 2008 Oct; 103(1):33-7. PubMed ID: 18632105
[TBL] [Abstract][Full Text] [Related]
6. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
Rattanaburi A; Boonyapipat S; Supasinth Y
Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
[TBL] [Abstract][Full Text] [Related]
7. Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia.
Li L; Wan X; Feng F; Ren T; Yang J; Zhao J; Jiang F; Xiang Y
BMC Cancer; 2018 May; 18(1):585. PubMed ID: 29792175
[TBL] [Abstract][Full Text] [Related]
8. Response to chemotherapy in overweight/obese patients with low-risk gestational trophoblastic neoplasia.
Maestá I; Horowitz NS; Goldstein DP; Bernstein MR; RamÃrez LA; Moulder J; Berkowitz RS
Int J Gynecol Cancer; 2015 May; 25(4):734-40. PubMed ID: 25675037
[TBL] [Abstract][Full Text] [Related]
9. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
Chen YX; Shen YM; Qian JH; Xie X
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Second-Line 5-Day Dactinomycin in Case of Methotrexate Failure for Gestational Trophoblastic Neoplasia.
Prouvot C; Golfier F; Massardier J; You B; Lotz JP; Patrier S; Devouassoux M; Schott AM; Hajri T; Bolze PA
Int J Gynecol Cancer; 2018 Jun; 28(5):1038-1044. PubMed ID: 29629964
[TBL] [Abstract][Full Text] [Related]
11. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
[No Abstract] [Full Text] [Related]
12. Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia.
Lurain JR; Chapman-Davis E; Hoekstra AV; Schink JC
J Reprod Med; 2012; 57(7-8):283-7. PubMed ID: 22838241
[TBL] [Abstract][Full Text] [Related]
13. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
[TBL] [Abstract][Full Text] [Related]
14. Combined methotrexate-dactinomycin: an effective therapy for low-risk gestational trophoblastic neoplasia.
Eiriksson L; Wells T; Steed H; Schepansky A; Capstick V; Hoskins P; Pike J; Swenerton K
Gynecol Oncol; 2012 Mar; 124(3):553-7. PubMed ID: 22079360
[TBL] [Abstract][Full Text] [Related]
15. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
[TBL] [Abstract][Full Text] [Related]
16. Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: factors associated with resistance to single-agent methotrexate chemotherapy.
Chapman-Davis E; Hoekstra AV; Rademaker AW; Schink JC; Lurain JR
Gynecol Oncol; 2012 Jun; 125(3):572-5. PubMed ID: 22449733
[TBL] [Abstract][Full Text] [Related]
17. Treatment of low-risk gestational trophoblastic neoplasia comparing biweekly eight-day Methotrexate with folinic acid versus bolus-dose Actinomycin-D, among Brazilian women.
Uberti EM; Fajardo Mdo C; da Cunha AG; Frota SS; Braga A; Ayub AC
Rev Bras Ginecol Obstet; 2015 Jun; 37(6):258-65. PubMed ID: 26200823
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and prognosis of ultra high-risk gestational trophoblastic neoplasia patients: A retrospective cohort study.
Kong Y; Yang J; Jiang F; Zhao J; Ren T; Li J; Wang X; Feng F; Wan X; Xiang Y
Gynecol Oncol; 2017 Jul; 146(1):81-86. PubMed ID: 28461032
[TBL] [Abstract][Full Text] [Related]
19. Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia.
Chen LM; Lengyel ER; Bethan Powell C
Gynecol Oncol; 2004 Jul; 94(1):204-7. PubMed ID: 15262143
[TBL] [Abstract][Full Text] [Related]
20. Human chorionic gonadotropin (hCG) regression normograms for patients with high-risk gestational trophoblastic neoplasia treated with EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide and vincristine) chemotherapy.
Lybol C; Westerdijk K; Sweep FCGJ; Ottevanger PB; Massuger LFAG; Thomas CMG
Ann Oncol; 2012 Nov; 23(11):2903-2906. PubMed ID: 22730100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
